Spike (SARS-CoV-2) Lentivirus

78010-1

Spike (SARS-CoV-2) Lentivirus

Cell entry of SARS-CoV-2 depends on the binding of viral spike protein to cellular receptor ACE2. The SARS-CoV-2 Spike Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types mammalian cells, including primary and non-dividing cells. The particles contain the full length SARS-CoV-2 spike gene (QHD43416.1) driven by an EF1a promoter._x000D_

1402.5 €

79981-1

Spike (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter)

The SARS-CoV-2 Spike Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions also contain the enhanced GFP gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently determined via eGFP activity. The SARS-CoV-2 Spike pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_

1462.5 €

79981-2

Spike (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter)

The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_The SARS-CoV-2 Spike Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions also contain the enhanced GFP gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently determined via eGFP activity. The SARS-CoV-2 Spike pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_

8017.5 €

MBS154645-5x005mg

SARS-CoV-2 Spike Peptide

1332.5 €

MBS154646-005mg

SARS-CoV-2 Spike Peptide

446.38 €

MBS154646-5x005mg

SARS-CoV-2 Spike Peptide

1332.5 €